news

CUPERTINO, Calif., Feb. 20, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced it will host a key opinion leader (KOL) call on the treatment of primary sclerosing cholangitis (PSC) on Monday, February 26 at 12:00 p.m. Eastern Time. The call will feature a presentation by KOL Keith Lindor, MD, who will present an overview of […]

CUPERTINO, Calif., Feb. 14, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE), reported yesterday that it has resubmitted the New Drug Application (NDA) for REMOXY® ER to the U.S. Food and Drug Administration (FDA).  REMOXY ER is designed as an abuse-deterrent, extended release, capsule formulation of oxycodone,

CUPERTINO, Calif., Dec. 13, 2017 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Indivior PLC (LON: INDV) has reported that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for RBP-7000.  RBP-7000 is an investigational, once-monthly injectable risperidone for the treatment of schizophrenia. Indivior PLC further reported that the FDA

Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif., Nov. 1, 2017 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2017 and provided a corporate update.   Executed a patent purchase agreement with Indivior relevant to Indivior’s RBP-7000, yielding DURECT a $12.5 million

CUPERTINO, Calif., Oct. 26, 2017 /PRNewswire/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) third quarter 2017 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Wednesday, November 1, 2017 at 4:30 pm Eastern Time (1:30 pm Pacific Time). A live audio webcast

CUPERTINO, Calif., Oct. 19, 2017 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today reported that PERSIST, the Phase 3 clinical trial for POSIMIR® (SABER®-Bupivacaine), did not meet its primary efficacy endpoint of reduction in pain on movement over the first 48 hours after surgery as compared to standard bupivacaine HCl.  While results trended in favor of POSIMIR versus

Agreement Relates to Intellectual Property for RBP-7000, Indivior’s Investigational Once-Monthly Injectable Risperidone Product for Schizophrenia CUPERTINO, Calif., Oct. 2, 2017 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced a patent purchase agreement with Indivior UK Limited, an affiliate of Indivior PLC (LON: INDV), whereby DURECT has assigned certain of its U.S. patent rights to Indivior. This

CUPERTINO, Calif., Sept. 20, 2017 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that Dr. Myriam Theeuwes has joined DURECT as Senior Vice President, Clinical Development.  Dr. Theeuwes joins DURECT from Johnson & Johnson where she spent 18 years, most recently as Compound Development Team Leader for Janssen Pharmaceutical’s global public health initiatives where she

CUPERTINO, Calif., Sept. 5, 2017 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming investment conferences.  James E. Brown, President and CEO, will present at the Rodman & Renshaw Global Investment Conference on Tuesday, September 12 at 12:30 p.m. Eastern time. The conference is being held at

Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif., Aug. 8, 2017 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2017 and provided a corporate update.   Executed a U.S. commercialization agreement with Sandoz for POSIMIR®, including a $20 million upfront payment, as